磺脲受体1基因外显子16-3c/t多态性与格列齐特降血糖的关系  

Relationship between the polymorphism of sylfonylurea receptor 1 extron 16-3c/t and decreased the blood glucose of gliclazide

作　　者：张慧娟[1] 刘晓民[1] 匡洪宇[1] 孙宏[2] 邢厚恂[3] 

机构地区：[1]哈尔滨医科大学第一临床医院内分泌科,哈尔滨150001 [2]哈尔滨医科大学公共卫生学院,哈尔滨150001 [3]安徽省生物医学研究所,合肥230022

出　　处：《中国临床药理学杂志》2007年第5期369-371,共3页The Chinese Journal of Clinical Pharmacology

基　　金：国家自然科学基金资助项目(30671802);黑龙江省卫生厅医学科研课题资助项目(2006-014);黑龙江省教育厅科研课题资助项目(11521122)

摘　　要：目的研究磺脲类药物受体1(SUR1)基因多态性与格列齐特降糖疗效的关系。方法用Taqman-PCR技术检测119例2型糖尿病患者SUR1基因型,分析基因型与血糖变化的关系。结果SUR1基因16外显子-3c/t位点的突变纯合子tt基因型患者,其基线空腹胰岛素水平高于野生纯合子cc基因型患者(P<0.05)。格列齐特治疗后,各基因型空腹血糖、餐后2h血糖、糖化血红蛋白、空腹胰岛素及胰岛素抵抗指数下降幅度均无显著性差异。结论16外显子-3c/t多态性与格列齐特降糖疗效无关。Objective To investigate the relationshipe between the polymorphism of sulfonylurea receptor 1 （ SUR1 ） extron 16 - 3c/t and decreased the blood glucose of gliclazide. Methods SUR1 genotypes of 119 patients with type 2 diabetes were determined by Taqman - PCR. The association between the drug efficacy and genotypes was investigated. Results At baseline, the serum insulin of the group with tt genotype of SUR1 extron 16 - 3c/t was significantly higher than that of the group with cc genotype（ P 〈 0.05 ）. After treatment extron 16 - 3c/t gene polymorphism was no associated with decrease of FPG, 2hPG, HbA1 c, FINS and HOMA - IR （P 〉0.05）. Conclusion Extron 16 -3c/t gene polymorphism was no associated with the therapeutic efficacy of gliclazide, but related to insulin level.

关 键 词：2型糖尿病 基因多态性 格列齐特 

分 类 号：R587.1[医药卫生—内分泌] R977.15[医药卫生—内科学]